Supernus Pharmaceuticals Company Profile (NASDAQ:SUPN)

About Supernus Pharmaceuticals

Supernus Pharmaceuticals logoSupernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company offers products for the treatment of epilepsy, which include extended-release oxcarbazepine (Oxtellar XR) and extended-release topiramate (Trokendi XR). It develops multiple product candidates in psychiatry for the treatment of Impulsive Aggression (IA) and attention deficit hyperactivity disorder (ADHD). Its psychiatry product candidates include SPN-810 (molindone hydrochloride) and SPN-812 (viloxazine hydrochloride). It is also developing SPN-810 as a treatment for IA in patients who have ADHD and SPN-812 for the treatment of ADHD. It is developing SPN-809 (viloxazine hydrochloride) for the treatment of depression. It markets its products in the United States through its own specialty sales force and has collaborations with other pharmaceutical companies to license its products outside the United States.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: SUPN
  • CUSIP: 86845910
Key Metrics:
  • Previous Close: $26.58
  • 50 Day Moving Average: $23.12
  • 200 Day Moving Average: $19.56
  • 52-Week Range: $9.51 - $26.84
  • Trailing P/E Ratio: 53.16
  • Foreward P/E Ratio: 19.47
  • P/E Growth: 0.52
  • Market Cap: $1.29B
  • Outstanding Shares: 49,508,000
  • Beta: 1.77
Profitability:
  • Net Margins: 14.94%
  • Return on Equity: 20.99%
  • Return on Assets: 13.58%
Debt:
  • Debt-to-Equity Ratio: 0.04%
  • Current Ratio: 1.74%
  • Quick Ratio: 1.49%
Additional Links:
Companies Related to Supernus Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Supernus Pharmaceuticals (NASDAQ:SUPN) (?)
Ratings Breakdown: 2 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 2.33)
Consensus Price Target: $25.00 (6.30% downside)

Analysts' Ratings History for Supernus Pharmaceuticals (NASDAQ:SUPN)
Show:
DateFirmActionRatingPrice TargetDetails
8/4/2016Jefferies GroupReiterated RatingBuy$23.00 -> $28.00View Rating Details
7/18/2016Northland SecuritiesDowngradeOutperform -> Market Perform$24.00View Rating Details
7/18/2016Piper Jaffray Cos.DowngradeOverweight -> Neutral$23.00View Rating Details
6/18/2015Stifel NicolausBoost Price TargetBuy$15.00 -> $22.00View Rating Details
6/12/2015SunTrust Banks Inc.Initiated CoverageBuy$30.00View Rating Details
6/9/2015GuggenheimInitiated CoverageBuy$21.00View Rating Details
(Data available from 9/28/2014 forward)

Earnings

Earnings History for Supernus Pharmaceuticals (NASDAQ:SUPN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/1/2016        
8/2/2016Q2$0.13$0.18$49.67 million$50.40 millionViewListenView Earnings Details
5/3/2016Q1$0.09$0.08$45.33 million$43.00 millionViewListenView Earnings Details
3/2/2016Q4$0.06$0.14$42.93 million$42.70 millionViewListenView Earnings Details
11/3/2015Q315$0.02$0.08$37.93 million$38.60 millionViewListenView Earnings Details
8/5/2015Q215$0.02$0.03$34.07 million$35.10 millionViewListenView Earnings Details
5/5/2015$0.02$0.02$29.16 million$28.13 millionViewListenView Earnings Details
11/11/2014Q314$0.36$0.39$43.10 million$52.50 millionViewN/AView Earnings Details
8/11/2014Q214($0.16)$0.08$19.85 million$29.67 millionViewN/AView Earnings Details
5/12/2014Q114($0.41)($0.38)$9.94 million$9.00 millionViewN/AView Earnings Details
3/12/2014Q413($0.55)($0.65)$7.78 million$10.30 millionViewN/AView Earnings Details
11/12/2013Q313($0.67)($0.78)$2.54 million$1.26 millionViewListenView Earnings Details
8/13/2013Q2 2013($0.65)($0.89)$0.91 million$0.28 millionViewN/AView Earnings Details
11/7/2012Q312($0.62)($0.55)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Supernus Pharmaceuticals (NASDAQ:SUPN)
Current Year EPS Consensus Estimate: $0.68 EPS
Next Year EPS Consensus Estimate: $1.37 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163$0.06$0.10$0.08
Q2 20162$0.13$0.13$0.13
Q3 20162$0.19$0.23$0.21
Q4 20162$0.16$0.28$0.22
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Supernus Pharmaceuticals (NASDAQ:SUPN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Supernus Pharmaceuticals (NASDAQ:SUPN)
Insider Ownership Percentage: 6.10%
Institutional Ownership Percentage: 94.66%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/16/2016Gregory S PatrickCFOSell2,000$25.00$50,000.00View SEC Filing  
7/14/2016Gregory S. PatrickCFOSell3,395$22.00$74,690.00View SEC Filing  
4/11/2016Padmanabh P BhattVPSell30,762$16.49$507,265.38View SEC Filing  
12/9/2015Padmanabh P. BhattVPSell14,238$14.90$212,146.20View SEC Filing  
12/8/2015M James BarrettDirectorSell212,970$14.56$3,100,843.20View SEC Filing  
11/25/2015M James BarrettDirectorSell16,179$16.35$264,526.65View SEC Filing  
11/18/2015M James BarrettDirectorSell93,000$16.61$1,544,730.00View SEC Filing  
11/16/2015M James BarrettDirectorSell119,650$16.24$1,943,116.00View SEC Filing  
11/4/2015Padmanabh P BhattVPSell5,000$19.90$99,500.00View SEC Filing  
7/16/2015Gregory S PatrickCFOSell6,217$20.00$124,340.00View SEC Filing  
7/13/2015Stefan K.F. SchwabeEVPSell1,950$19.23$37,498.50View SEC Filing  
6/17/2015M James BarrettDirectorSell111,881$16.39$1,833,729.59View SEC Filing  
6/17/2015Scott D SandellMajor ShareholderSell136,597$16.50$2,253,850.50View SEC Filing  
6/16/2015M James BarrettDirectorSell55,105$16.85$928,519.25View SEC Filing  
6/16/2015Scott D SandellMajor ShareholderSell95,437$16.92$1,614,794.04View SEC Filing  
6/12/2015Stefan K.F. SchwabeEVPSell2,051$18.27$37,471.77View SEC Filing  
6/11/2015Stefan K.F. SchwabeEVPSell3,631$16.39$59,512.09View SEC Filing  
3/24/2015Jones W BryanVPSell1,900$12.00$22,800.00View SEC Filing  
8/19/2013Padmanabh BhattVPSell2,285$8.21$18,759.85View SEC Filing  
3/22/2013Michael BighamDirectorBuy35,000$5.41$189,350.00View SEC Filing  
3/21/2013John M SiebertDirectorBuy3,000$5.50$16,500.00View SEC Filing  
3/15/2013Jack A KhattarCEOBuy10,000$6.15$61,500.00View SEC Filing  
3/14/2013Gregory S PatrickCFOBuy5,000$6.95$34,750.00View SEC Filing  
12/4/2012John M SiebertDirectorBuy7,000$8.14$56,980.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Supernus Pharmaceuticals (NASDAQ:SUPN)
DateHeadline
News IconShares Have Ticked Up Over the Last Five Trading Sessions: Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Post News (NASDAQ:SUPN)
www.kentuckypostnews.com - September 20 at 10:41 AM
investors.com logoNasdaq Erases Gains But Small Caps Strong Ahead Of Fed (NASDAQ:SUPN)
www.investors.com - September 19 at 7:27 PM
thestreet.com logoSeeing the Same Old Patterns Ahead of Fed News (NASDAQ:SUPN)
realmoney.thestreet.com - September 19 at 11:18 AM
investornewswire.com logoSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Posted A ... - Investor Newswire (NASDAQ:SUPN)
www.investornewswire.com - September 18 at 6:57 PM
News IconSafe Haven Investment Portfolio Stocks: Boston Scientific (NYSE:BSX), Supernus Pharmaceuticals (NASDAQ:SUPN) - Street Wise Report (press release) (blog) (NASDAQ:SUPN)
streetwisereport.com - September 16 at 11:04 AM
News IconAnalyst Projections and Growth Recap for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Post News (NASDAQ:SUPN)
www.kentuckypostnews.com - September 15 at 7:36 PM
capitalcube.com logoETF’s with exposure to Supernus Pharmaceuticals, Inc. : September 15, 2016 (NASDAQ:SUPN)
www.capitalcube.com - September 15 at 11:11 AM
capitalcube.com logoSupernus Pharmaceuticals, Inc. – Value Analysis (NASDAQ:SUPN) : September 13, 2016 (NASDAQ:SUPN)
www.capitalcube.com - September 14 at 11:53 AM
capitalcube.com logoSupernus Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : SUPN-US : September 12, 2016 (NASDAQ:SUPN)
www.capitalcube.com - September 12 at 11:19 AM
News IconPlacing Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Under the Microscope (NASDAQ:SUPN)
www.nationaldailypress.com - September 10 at 11:16 AM
News IconPlacing Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Under the Microscope - National Daily Press (NASDAQ:SUPN)
www.nationaldailypress.com - September 9 at 11:19 AM
News IconSell-side is Weighing in on Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Earnings & Targets - Frisco Fastball (NASDAQ:SUPN)
friscofastball.com - September 7 at 7:38 PM
nasdaq.com logoCommit To Buy Supernus Pharmaceuticals At $17, Earn 7.1% Annualized Using Options (NASDAQ:SUPN)
www.nasdaq.com - September 2 at 7:25 PM
News IconShares Slipping Lower Over the Past Month: Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Post News (NASDAQ:SUPN)
www.kentuckypostnews.com - September 1 at 10:44 AM
capitalcube.com logoETF’s with exposure to Supernus Pharmaceuticals, Inc. : August 30, 2016 (NASDAQ:SUPN)
www.capitalcube.com - August 30 at 7:26 PM
capitalcube.com logoSupernus Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SUPN-US : August 29, 2016 (NASDAQ:SUPN)
www.capitalcube.com - August 29 at 7:31 PM
biz.yahoo.com logoSUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:SUPN)
biz.yahoo.com - August 24 at 7:20 PM
finance.yahoo.com logoSupernus' Trokendi XR Gets FDA Nod for Migraine in Adults (NASDAQ:SUPN)
finance.yahoo.com - August 22 at 11:04 AM
4-traders.com logoSupernus Pharmaceuticals : Receives FDA Tentative Approval for Expanded Label of Trokendi XR to Include Migraine Prophylaxis in Adults (NASDAQ:SUPN)
www.4-traders.com - August 20 at 11:37 AM
streetinsider.com logoSupernus Pharma (SUPN) Receives Tentative FDA Approval for Trokendi XR sNDA Label Expansion - StreetInsider.com (NASDAQ:SUPN)
www.streetinsider.com - August 19 at 7:32 PM
finance.yahoo.com logo2:37 pm Supernus Pharma receives tentative FDA approval to its sNDA requesting a label expansion for Trokendi XR to include prophylaxis of migraine headache in adults (NASDAQ:SUPN)
finance.yahoo.com - August 19 at 7:32 PM
finance.yahoo.com logoSupernus Receives FDA Tentative Approval for Expanded Label of Trokendi XR® to Include Migraine Prophylaxis in Adults (NASDAQ:SUPN)
finance.yahoo.com - August 19 at 7:32 PM
capitalcube.com logoETF’s with exposure to Supernus Pharmaceuticals, Inc. : August 16, 2016 (NASDAQ:SUPN)
www.capitalcube.com - August 16 at 7:45 PM
finance.yahoo.com logoSUPERNUS PHARMACEUTICALS INC Financials (NASDAQ:SUPN)
finance.yahoo.com - August 16 at 7:45 PM
biz.yahoo.com logoSUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and (NASDAQ:SUPN)
biz.yahoo.com - August 12 at 7:45 PM
publicnow.com logoSupernus Announces Resignation of Dr. James Barrett from Board of Directors; Charles W. Newhall, III Elected Chairman (NASDAQ:SUPN)
www.publicnow.com - August 12 at 7:45 PM
capitalcube.com logoSupernus Pharmaceuticals, Inc. :SUPN-US: Earnings Analysis: Q2, 2016 By the Numbers : August 9, 2016 (NASDAQ:SUPN)
www.capitalcube.com - August 9 at 7:57 PM
streetreport.co logoSupernus Pharmaceuticals Inc (NASDAQ:SUPN) Released Q2 Profit of $10 Million - Street Report (NASDAQ:SUPN)
www.streetreport.co - August 5 at 10:42 AM
biz.yahoo.com logoSUPERNUS PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report (NASDAQ:SUPN)
biz.yahoo.com - August 5 at 10:42 AM
finance.yahoo.com logoEdited Transcript of SUPN earnings conference call or presentation 3-Aug-16 1:00pm GMT (NASDAQ:SUPN)
finance.yahoo.com - August 4 at 10:51 AM
biz.yahoo.com logoSupernus Pharmaceuticals Inc Earnings Call scheduled for 9:00 am ET today (NASDAQ:SUPN)
biz.yahoo.com - August 3 at 10:54 AM
stockhouse.com logoSupernus Announces Second Quarter 2016 Financial Results (NASDAQ:SUPN)
www.stockhouse.com - August 2 at 7:59 PM
sg.finance.yahoo.com logoSupernus tops 2Q profit forecasts (NASDAQ:SUPN)
sg.finance.yahoo.com - August 2 at 7:59 PM
tradecalls.org logoHealthinvest Partners Ab Lowers stake in Supernus Pharmaceuticals Inc (SUPN) - Trade Calls (NASDAQ:SUPN)
www.tradecalls.org - August 2 at 11:34 AM
biz.yahoo.com logoQ2 2016 Supernus Pharmaceuticals Inc Earnings Release - After Market Close (NASDAQ:SUPN)
biz.yahoo.com - August 2 at 11:34 AM
News IconIt's Earnings Time: What to Do with Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Stock - The Voice Registrar (NASDAQ:SUPN)
voiceregistrar.com - July 30 at 10:23 AM
investornewswire.com logoCan Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Keep Up ... - Investor Newswire (NASDAQ:SUPN)
www.investornewswire.com - July 27 at 8:04 PM
capitalcube.com logoETF’s with exposure to Supernus Pharmaceuticals, Inc. : July 26, 2016 (NASDAQ:SUPN)
www.capitalcube.com - July 26 at 1:01 PM
tradecalls.org logoNorthland Securities Downgrades Supernus Pharmaceuticals Inc to Market Perform - Trade Calls (NASDAQ:SUPN)
www.tradecalls.org - July 26 at 11:04 AM
fiscalstandard.com logoBroker Outlook For Supernus Pharmaceuticals, Inc. (SUPN) - Fiscal Standard (NASDAQ:SUPN)
www.fiscalstandard.com - July 23 at 11:25 AM
News IconOpaleye Management INC Decreased Stake in Supernus Pharmaceuticals INC (NASDAQ:SUPN) by $4.43 Million as ... - Press Telegraph (NASDAQ:SUPN)
presstelegraph.com - July 23 at 11:25 AM
News IconHow Many Supernus Pharmaceuticals Inc (NASDAQ:SUPN)'s Analysts Are Bearish? - Consumer Eagle (NASDAQ:SUPN)
www.consumereagle.com - July 21 at 10:28 AM
News IconJuncture Wealth Strategies Lowers stake in Supernus Pharmaceuticals Inc (SUPN) - TheFounders Daily (NASDAQ:SUPN)
www.thefoundersdaily.com - July 20 at 8:38 PM
biz.yahoo.com logoSUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements (NASDAQ:SUPN)
biz.yahoo.com - July 20 at 4:36 PM
finance.yahoo.com logoSupernus to Host Second Quarter 2016 Earnings Conference Call (NASDAQ:SUPN)
finance.yahoo.com - July 20 at 4:30 PM
News IconSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily (NASDAQ:SUPN)
www.engelwooddaily.com - July 19 at 8:37 AM
finance.yahoo.com logoSupernus Pharma downgraded by Piper Jaffray and Northland Capital (NASDAQ:SUPN)
finance.yahoo.com - July 18 at 6:35 AM
News IconIncreased Volatility Noted on Shares of: Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Engelwood Daily (NASDAQ:SUPN)
www.engelwooddaily.com - July 16 at 10:49 AM
News IconCrowd Rating and Earnings Recap for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Telanagana Press (NASDAQ:SUPN)
telanaganapress.com - July 15 at 12:53 PM
News IconMurphy Michael R Decreased Stake in Supernus Pharmaceuticals INC (NASDAQ:SUPN) by $5.68 Million as Shares ... - Consumer Eagle (NASDAQ:SUPN)
www.consumereagle.com - July 15 at 12:53 PM

Social

Supernus Pharmaceuticals (NASDAQ:SUPN) Chart for Wednesday, September, 28, 2016


Last Updated on 9/28/2016 by MarketBeat.com Staff